Role 2 Afloat provides a damage control resuscitation and surgery facility in support of maritime, littoral and aviation operations. Resuscitative endovascular balloon occlusion of the aorta (REBOA) offers a rapid, effective solution to exsanguinating haemorrhage from pelvic and non-compressible torso haemorrhage. It should be considered when the patient presents in a peri-arrest state, if surgery is likely to be delayed, or where the single operating table is occupied by another case. This paper will outline the data in support of endovascular haemorrhage control, describe the technique and explore how REBOA could be delivered using equipment currently available in the Royal Navy Role 2 Afloat equipment module. Also discussed are potential...
The aim of this thesis is to provide further evidence for the potential benefits of the use of advan...
International audienceBACKGROUND:Resuscitative endovascular balloon occlusion of the aorta (REBOA) i...
Acknowledgements The UK-REBOA trial grantholders include Jan O. Jansen, University of Aberdeen, UK, ...
Role 2 Afloat provides a damage control resuscitation and surgery facility in support of maritime, l...
PURPOSE OF REVIEW: Hemorrhage is the major cause of early death in severely injured patients. In ci...
Currently, resuscitative endovascular balloon occlusion of the aorta (REBOA) is used in trauma surge...
PURPOSE OF REVIEW: Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally ...
It is extremely difficult to provide non-compressible torso hemorrhage control particularly in traum...
AIM: To report the initial experience and outcomes of Resuscitative Endovascular Balloon Occlusion o...
Established in 2018, the Defence Endovascular Resuscitation (DefER) group recognised that resuscitat...
Introduction: Exsanguination due to hemorrhage is the leading cause of death in victims of abdomino-...
Introduction Resuscitative endovascular balloon occlusion of the aorta (REBOA) is rapidly evolving a...
Hemorrhage is the single largest cause of avoidable death in trauma patients, whereby in civil emerg...
Despite the success of prehospital resuscitative endovascular balloon occlusion of the aorta (REBOA)...
Early hemorrhage control using resuscitative endovascular balloon occlusion of the aorta (REBOA) can...
The aim of this thesis is to provide further evidence for the potential benefits of the use of advan...
International audienceBACKGROUND:Resuscitative endovascular balloon occlusion of the aorta (REBOA) i...
Acknowledgements The UK-REBOA trial grantholders include Jan O. Jansen, University of Aberdeen, UK, ...
Role 2 Afloat provides a damage control resuscitation and surgery facility in support of maritime, l...
PURPOSE OF REVIEW: Hemorrhage is the major cause of early death in severely injured patients. In ci...
Currently, resuscitative endovascular balloon occlusion of the aorta (REBOA) is used in trauma surge...
PURPOSE OF REVIEW: Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally ...
It is extremely difficult to provide non-compressible torso hemorrhage control particularly in traum...
AIM: To report the initial experience and outcomes of Resuscitative Endovascular Balloon Occlusion o...
Established in 2018, the Defence Endovascular Resuscitation (DefER) group recognised that resuscitat...
Introduction: Exsanguination due to hemorrhage is the leading cause of death in victims of abdomino-...
Introduction Resuscitative endovascular balloon occlusion of the aorta (REBOA) is rapidly evolving a...
Hemorrhage is the single largest cause of avoidable death in trauma patients, whereby in civil emerg...
Despite the success of prehospital resuscitative endovascular balloon occlusion of the aorta (REBOA)...
Early hemorrhage control using resuscitative endovascular balloon occlusion of the aorta (REBOA) can...
The aim of this thesis is to provide further evidence for the potential benefits of the use of advan...
International audienceBACKGROUND:Resuscitative endovascular balloon occlusion of the aorta (REBOA) i...
Acknowledgements The UK-REBOA trial grantholders include Jan O. Jansen, University of Aberdeen, UK, ...